Tuesday, November 19, 2024
Home Superbug News - CoronaVirus Watch List Page 14

Superbug News - CoronaVirus Watch List

    The Superbug Stock Review. Deadly Antibiotic-Resistant Bacteria like ‘Candida Auris’ and Deadly and Virulent Viruses Like ‘CoronaVirus’ or ‘HIV’ which killed 32 million. If Wall Street Funded Biotechs Are Trying to Kill What Wants to Kill Us, We’ll Follow It.

    Latest
    Dyadic, Biotech Stock Review

    Dyadic (DYAI) Highlights.

    Biotech News Editor / Curator -
    "In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and...

    Adding Citius (CTXR) $0.55 to Watch List.

    Biotech News Editor / Curator -
    Best Presentation at Dawson James Conference. We attended the Dawson James Conference on October 29th, which had over 20...
    Dyadic, Biotech Stock Review

    Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.

    Biotech News Editor / Curator -
    Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.
    Dyadic

    Investor Presentation Slides From Dyadic (DYA) $6.40.

    Superbug News - CoronaVirus Watch List Editor / Curator -
    Really, How Do We Do It? Live Short Term Chart
    candida auris, citius pharma, biotech stock review

    Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.

    Biotech News Editor / Curator -
    CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug...
    1...121314Page 14 of 14

    Latest article

    Nine Page Summary Report on GeoVax (GOVX)

    2024 Watch List Editor / Curator -
    This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

    GeoVax (GOVX) Provides First Half 2024 Business Update.

    2024 Watch List Editor / Curator -
    Award of BARDA Project NextGen contract represents a significant milestone event; Total value...

    Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.

    All News Editor / Curator -
    Can You Imagine Selling Solgenix at $2.00 yesterday. And to be honest, news wasn't all that big - such...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.